Head of pharmaceuticals research and development, Christian Rommel, phrased it to sister publication Scrip at the J.P. Morgan Healthcare conference as the company going through a “resilience phase.” Also see "Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs" - Scrip, 18 January, 2024.
And with all hands on deck, Juergen Eckhardt, head of Bayer AG’s pharmaceuticals business development and licensing/open innovation, will...